Therefore, NALM6 cells were treated with KN-93, an established CaMKII pharmacological inhibitor, to determine if CaMKII is functionally important in pre-B ALL maturation [17,67,68]. The gene discussed is CAMK2G; the disease is acute lymphoblastic leukemia.